Zelnorm was relaunched by Alfasigma USA for the treatment of irritable bowel syndrome with constipation (IBS-C).

The Trump administration announced plans to remove all flavored e-cigarettes from store shelves in a widening crackdown on vaping, as officials warned that sweet flavors had drawn millions of children into nicotine addiction.

OxyContin maker Purdue Pharma LP reached a tentative agreement with some plaintiffs to resolve litigation over the company’s alleged role in fueling the U.S. opioid crisis and plans to tussle with states opposing the settlement offer in bankruptcy proceedings, people familiar with the matter said.

GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and the company’s transglutaminase 2 small molecule program for celiac disease.

Lexicon Pharmaceuticals Inc. said France’s Sanofi SA will pay the Texas-based drugmaker $260 million for the termination of their partnership to develop the diabetes drug Zynquista.

Health investigators are casting a wide net to understand what is sickening hundreds of vapers across the United States and still have not ruled out any product on the market.

Cognoa and Eversana announced a partnership to advance the industry standard by which digital medicines will be ordered, dispensed, and covered by insurance.

Mallinckrodt plc agreed to sell the global biopharmaceutical company’s wholly owned subsidiary BioVectra Inc. to an affiliate of private equity investment firm H.I.G. Capital for $250 million.

Neurotrope Inc.’s shares tumbled nearly 80 percent after the company said the drug developer’s experimental Alzheimer’s disease treatment Bryostatin-1 did not meet the main goal of a mid-stage study.

Syneos Health showcased Syneos Health Deployment Solutions at the Future Pharma Conference in Boston. Advancing the traditional outsourced field sales model, Deployment Solutions delivers a customized, integrated mix of promotional and educational channels purposefully designed to ensure successful commercialization.